Thursday, September 29, 2016

Vicks VapoSteam Liquid


Pronunciation: KAM-for
Generic Name: Camphor
Brand Name: Vicks VapoSteam


Vicks VapoSteam Liquid is used for:

Temporarily relieving cough due to the common cold. It is used along with a steam vaporizer. It may also be used for other conditions as determined by your doctor.


Vicks VapoSteam Liquid is a cough suppressant. It works by helping steam to moisten breathing passages.


Do NOT use Vicks VapoSteam Liquid if:


  • you are allergic to any ingredient in Vicks VapoSteam Liquid

Contact your doctor or health care provider right away if any of these apply to you.



Before using Vicks VapoSteam Liquid:


Some medical conditions may interact with Vicks VapoSteam Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you have a persistent cough (eg, due to smoking), breathing or lung problems (eg, asthma, emphysema), or a cough with a lot of mucus

Some MEDICINES MAY INTERACT with Vicks VapoSteam Liquid. However, no specific interactions with Vicks VapoSteam Liquid are known at this time.


Ask your health care provider if Vicks VapoSteam Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Vicks VapoSteam Liquid:


Use Vicks VapoSteam Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Add Vicks VapoSteam Liquid to cold water only in a hot steam vaporizer as directed by your doctor or on the product label.

  • Follow the manufacturer's directions for using a vaporizer. Ask your doctor or pharmacist if you have any questions on how to use a vaporizer.

  • Breathe in medicated vapors. Do not allow steam to get too close to your face.

  • If you miss a dose of Vicks VapoSteam Liquid, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Vicks VapoSteam Liquid.



Important safety information:


  • Vicks VapoSteam Liquid may cause harm if it is swallowed. If you may have taken it by mouth, contact your poison control center or emergency room right away.

  • Vicks VapoSteam Liquid is for external use only. Do not take it by mouth. Do not get Vicks VapoSteam Liquid in your eyes. If you get it in your eyes, rinse at once with cool water.

  • Vicks VapoSteam Liquid is flammable. Do not use it near an open flame. Do not heat or microwave Vicks VapoSteam Liquid.

  • If your symptoms do not get better within 7 days, get worse, or if you develop a high fever or persistent headache, check with your doctor.

  • Vicks VapoSteam Liquid should not be used in CHILDREN younger than 2 years old without first checking with your child's doctor; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Vicks VapoSteam Liquid while you are pregnant. If you are or will be breast-feeding while you use Vicks VapoSteam Liquid, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Vicks VapoSteam Liquid:


All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Vicks VapoSteam Liquid. Seek medical attention right away if any of these SEVERE side effects occur:



Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Vicks VapoSteam side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Vicks VapoSteam Liquid:

Store Vicks VapoSteam Liquid at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat. Keep Vicks VapoSteam Liquid out of the reach of children and away from pets.


General information:


  • If you have any questions about Vicks VapoSteam Liquid, please talk with your doctor, pharmacist, or other health care provider.

  • Vicks VapoSteam Liquid is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Vicks VapoSteam Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Vicks VapoSteam resources


  • Vicks VapoSteam Side Effects (in more detail)
  • Vicks VapoSteam Use in Pregnancy & Breastfeeding
  • Vicks VapoSteam Support Group
  • 0 Reviews · Be the first to review/rate this drug

Vitapap


Generic Name: acetaminophen (oral) (a SEET a MIN oh fen)

Brand Names: Acetaminophen Quickmelt, Actamin, Adprin B, Anacin AF, Apra, Bromo Seltzer, Children's Tylenol, Children's Tylenol Meltaway, Ed-APAP, Elixsure Fever/Pain, Genebs, Infants Tylenol Concentrated Drops, Leader 8 Hour Pain Reliever, Little Fevers, Little Fevers Children's Fever/Pain Reliever, Mapap, Mapap Arthritis Pain, Mapap Extra Strength Rapid Burst, Mapap Infant Drops, Mapap Infants', Mapap Meltaway, Mapap Rapid Release Gelcaps, Mapap Rapid Tabs, Medi-Tabs, Q-Pap, Q-Pap Extra Strength, Silapap Childrens, Silapap Infants, St. Joseph Aspirin-Free, Tactinal, Tempra, Tempra Quicklets, Triaminic Fever & Pain, Triaminic Infant Drops, Tycolene, Tylenol, Tylenol Arthritis Caplet, Tylenol Arthritis Gelcap, Tylenol Caplet, Tylenol Caplet Extra Strength, Tylenol Childrens, Tylenol Cool Caplet Extra Strength, Tylenol Extra Strength, Tylenol Extra Strength Cool Caplet, Tylenol Extra Strength EZ, Tylenol Gelcap Extra Strength, Tylenol Geltab Extra Strength, Tylenol Infant's Drops, Tylenol Junior Meltaway, Tylenol Rapid Release Gelcap, Tylenol Sore Throat Daytime, Vitapap


What is acetaminophen?

There are many brands and forms of acetaminophen available and not all brands are listed on this leaflet.


Acetaminophen is a pain reliever and a fever reducer.


Acetaminophen is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers.


Acetaminophen may also be used for purposes not listed in this medication guide.


What is the most important information I should know about acetaminophen?


There are many brands and forms of acetaminophen available and not all brands are listed on this leaflet.


Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death.

Know the amount of acetaminophen in the specific product you are taking.


Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take acetaminophen. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you have liver disease or a history of alcoholism.


Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP.

What should I discuss with my healthcare provider before taking acetaminophen?


You should not take acetaminophen if you are allergic to it.

Ask a doctor or pharmacist if it is safe for you to take acetaminophen if you have:


  • liver disease; or


  • a history of alcoholism.




Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take acetaminophen. It is not known whether acetaminophen will harm an unborn baby. Before taking acetaminophen, tell your doctor if you are pregnant. Acetaminophen can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not give the medication to a child younger than 2 years old without the advice of a doctor.

How should I take acetaminophen?


Take exactly as directed on the label, or as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended.


Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death.

Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


If you are treating a child, use a pediatric form of acetaminophen. Use only the special dose-measuring dropper or oral syringe that comes with the specific pediatric form you are using. Carefully follow the dosing directions on the medicine label. Acetaminophen made for infants is available in two different dose concentrations, and each concentration comes with its own medicine dropper or oral syringe. These dosing devices are not equal between the different concentrations. Using the wrong device may cause you to give your child an overdose of acetaminophen. Never mix and match dosing devices between infant formulations of acetaminophen. You may need to shake the liquid before each use. Follow the directions on the medicine label.

The chewable tablet must be chewed thoroughly before you swallow it.


Make sure your hands are dry when handling the acetaminophen disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.


To use the acetaminophen effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.


Stop taking acetaminophen and call your doctor if:

  • you still have a fever after 3 days of use;




  • you still have pain after 7 days of use (or 5 days if treating a child);




  • you have a skin rash, ongoing headache, or any redness or swelling; or




  • if your symptoms get worse, or if you have any new symptoms.



This medication can cause unusual results with certain lab tests for glucose (sugar) in the urine. Tell any doctor who treats you that you are using acetaminophen.


Store at room temperature away from heat and moisture.

What happens if I miss a dose?


Since acetaminophen is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of acetaminophen can be fatal.

The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.


What should I avoid while taking acetaminophen?


Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen.

Acetaminophen side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking this medication and call your doctor at once if you have a serious side effect such as:

  • nausea, upper stomach pain, itching, loss of appetite;




  • dark urine, clay-colored stools; or




  • jaundice (yellowing of the skin or eyes).



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect acetaminophen?


Ask a doctor or pharmacist if it is safe for you to use acetaminophen if you are also using any of the following drugs:



  • an antibiotic, antifungal medicine, sulfa drug, or tuberculosis medicine;




  • birth control pills or hormone replacement therapy;




  • blood pressure medication;




  • cancer medications;




  • cholesterol-lowering medications such as Lipitor, Niaspan, Zocor, Vytorin, and others;




  • gout or arthritis medications (including gold injections);




  • HIV/AIDS medications;




  • medicines to treat psychiatric disorders;




  • an NSAID such as Advil, Aleve, Arthrotec, Cataflam, Celebrex, Indocin, Motrin, Naprosyn, Treximet, Voltaren, others; or




  • seizure medications.



This list is not complete and there may be other drugs that can interact with acetaminophen. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Vitapap resources


  • Vitapap Side Effects (in more detail)
  • Vitapap Use in Pregnancy & Breastfeeding
  • Vitapap Drug Interactions
  • Vitapap Support Group
  • 1 Review for Vitapap - Add your own review/rating


  • acetaminophen Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information

  • Acetaminophen MedFacts Consumer Leaflet (Wolters Kluwer)

  • Acetaminophen Monograph (AHFS DI)

  • Acetazolamide Monograph (AHFS DI)

  • Apra Advanced Consumer (Micromedex) - Includes Dosage Information

  • Apraclonidine Hydrochloride Monograph (AHFS DI)

  • Genapap Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Mapap Suppositories MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ofirmev Consumer Overview

  • Ofirmev Injection MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ofirmev Prescribing Information (FDA)

  • Paracetamol Consumer Overview

  • Tempra 1 Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Tylenol Consumer Overview

  • Tylenol MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Vitapap with other medications


  • Fever
  • Muscle Pain
  • Pain
  • Sciatica


Where can I get more information?


  • Your pharmacist can provide more information about acetaminophen.

See also: Vitapap side effects (in more detail)


Vitamin D3



Generic Name: cholecalciferol (vitamin D3) (KOE le kal SIF e role)

Brand Names: D 1000 IU, D3-5, D3-50, Delta D3, Vitamin D3


What is cholecalciferol?

Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body.


Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D, especially conditions of the skin or bones.


Cholecalciferol may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about cholecalciferol?


Do not use this medication if you have ever had an allergic reaction to vitamin D, or if you have high levels of calcium or vitamin D in your blood, or if you have any condition that makes it hard for your body to absorb nutrients from food (malabsorption).

Before taking cholecalciferol, tell your doctor if you are allergic to any drugs, or if you have heart disease, kidney disease, or an electrolyte imbalance.


Do not take other vitamin or mineral supplements unless your doctor has told you to.

Avoid using calcium supplements or antacids without your doctor's advice. Use only the specific type of supplement or antacid your doctor recommends. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of vitamin D can cause serious or life-threatening side effects.

Overdose symptoms may include headache, weakness, drowsiness, dry mouth, nausea, vomiting, constipation, muscle or bone pain, metallic taste in the mouth, weight loss, itchy skin, changes in heart rate, loss of interest in sex, confusion, unusual thoughts or behavior, severe pain in your upper stomach spreading to your back, or fainting.


What should I discuss with my healthcare provider before taking cholecalciferol?


Do not use this medication if you have ever had an allergic reaction to vitamin D, or if you have:

  • high levels of calcium in your blood (hypercalcemia);




  • high levels of vitamin D in your body (hypervitaminosis D); or




  • any condition that makes it hard for your body to absorb nutrients from food (malabsorption).



If you have any of these other conditions, you may need a dose adjustment or special tests to safely use cholecalciferol:



  • heart disease;




  • kidney disease; or




  • an electrolyte imbalance.




Your cholecalciferol dose needs may change if you are pregnant or breast-feeding. Tell your doctor if you are pregnant or plan to become pregnant during treatment, or if you are breast-feeding a baby.

How should I take cholecalciferol?


Take this medication exactly as directed on the label, or as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended.


Your doctor may occasionally change your dose to make sure you get the best results from this medication.


Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Cholecalciferol is only part of a complete program of treatment that may also include a special diet. It is very important to follow the diet plan created for you by your doctor or nutrition counselor. You should become very familiar with the list of foods you must eat or avoid to help control your condition.


Store this medication at room temperature away from moisture, light, and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of vitamin D can cause serious or life-threatening side effects.

Overdose symptoms may include headache, weakness, drowsiness, dry mouth, nausea, vomiting, constipation, muscle or bone pain, metallic taste in the mouth, weight loss, itchy skin, changes in heart rate, loss of interest in sex, confusion, unusual thoughts or behavior, severe pain in your upper stomach spreading to your back, or fainting.


What should I avoid while taking cholecalciferol?


Do not take other vitamin or mineral supplements unless your doctor has told you to.

Avoid using calcium supplements or antacids without your doctor's advice. Use only the specific type of supplement or antacid your doctor recommends.


Cholecalciferol side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking cholecalciferol and call your doctor at once if you have a serious side effect such as:

  • thinking problems, changes in behavior, feeling irritable;




  • urinating more than usual;




  • chest pain, feeling short of breath; or




  • early signs of vitamin D overdose (weakness, metallic taste in your mouth, weight loss, muscle or bone pain, constipation, nausea, and vomiting).



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect cholecalciferol?


Before taking cholecalciferol, tell your doctor if you are taking any of the following medicines:



  • seizure medication;




  • cholestyramine (Prevalite, Questran);




  • colestipol (Colestid);




  • steroids (prednisone and others);




  • digoxin (digitalis, Lanoxin); or




  • a diuretic (water pill) such as chlorothiazide (Diuril), hydrochlorothiazide (HCTZ, HydroDiuril, Hyzaar, Lopressor, Vasoretic, Zestoretic), chlorthalidone (Hygroton, Thalitone), indapamide (Lozol), metolazone (Mykrox, Zaroxolyn), and others.



This list is not complete and there may be other drugs that can interact with cholecalciferol. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Vitamin D3 resources


  • Vitamin D3 Side Effects (in more detail)
  • Vitamin D3 Use in Pregnancy & Breastfeeding
  • Vitamin D3 Drug Interactions
  • Vitamin D3 Support Group
  • 0 Reviews for Vitamin D3 - Add your own review/rating


  • Delta D3 Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Vitamin D3 with other medications


  • Prevention of Falls
  • Prevention of Fractures
  • Vitamin D Deficiency
  • Vitamin D Insufficiency


Where can I get more information?


  • Your pharmacist can provide more information about cholecalciferol.

See also: Vitamin D3 side effects (in more detail)


Vfend



voriconazole

Dosage Form: tablets, oral suspension, injection
FULL PRESCRIBING INFORMATION

Indications and Usage for Vfend


Vfend is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:



Invasive Aspergillosis


In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1), and Clinical Pharmacology (12.4)].



Candidemia in Non-neutropenic Patients and the Following Candida Infections: Disseminated Infections in Skin and Infections in Abdomen, Kidney, Bladder Wall, and Wounds


[see Clinical Studies (14.2), and Clinical Pharmacology (12.4)]



Esophageal Candidiasis


[see Clinical Studies (14.3), and Clinical Pharmacology (12.4)]



Serious Fungal Infections Caused by Scedosporium apiospermum (Asexual Form of Pseudallescheria boydii) and Fusarium spp. Including Fusarium solani, in Patients Intolerant of, or Refractory to, Other Therapy


[see Clinical Studies (14.4), and Clinical Pharmacology (12.4)]



Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.



Vfend Dosage and Administration



Instructions for Use in All Patients


Vfend Tablets or Oral Suspension should be taken at least one hour before or after a meal.


Vfend I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1 to 2 hours.


Do not administer as an IV bolus injection.



Use of Vfend I.V. With Other Parenteral Drug Products



Blood products and concentrated electrolytes


Vfend I.V. must not be infused concomitantly with any blood product or short-term infusion of concentrated electrolytes, even if the two infusions are running in separate intravenous lines (or cannulas). Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of Vfend therapy [see Warnings and Precautions (5.8)].



Intravenous solutions containing (non-concentrated) electrolytes


Vfend I.V. can be infused at the same time as other intravenous solutions containing (non-concentrated) electrolytes, but must be infused through a separate line.



Total parenteral nutrition (TPN)


Vfend I.V. can be infused at the same time as total parenteral nutrition, but must be infused in a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for Vfend I.V.



Recommended Dosing in Adults



Invasive aspergillosis and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum


See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous Vfend on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of Vfend may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults [see Clinical Pharmacology (12)].



Candidemia in non-neutropenic patients and other deep tissue Candida infections


See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer.



Esophageal Candidiasis


See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.












































Table 1: Recommended Dosing Regimen
InfectionLoading doseMaintenance Dose*,†
IVIVOral‡

*

Increase dose when Vfend is co-administered with phenytoin or efavirenz (7); Decrease dose in patients with hepatic impairment (2.7)

†

In healthy volunteer studies, the 200 mg oral q12h dose provided an exposure (AUCτ) similar to a 3 mg/kg IV q12h dose; the 300 mg oral q12h dose provided an exposure (AUCτ) similar to a 4 mg/kg IV q12h dose [see Clinical Pharmacology (12)].

‡

Adult patients who weigh less than 40 kg should receive half of the oral maintenance dose.

§

In a clinical study of invasive aspergillosis, the median duration of IV Vfend therapy was 10 days (range 2–90 days). The median duration of oral Vfend therapy was 76 days (range 2–232 days) [see Clinical Studies (14.1)].


In clinical trials, patients with candidemia received 3 mg/kg IV q12h as primary therapy, while patients with other deep tissue Candida infections received 4 mg/kg q12h as salvage therapy. Appropriate dose should be based on the severity and nature of the infection.

#

Not evaluated in patients with esophageal candidiasis.

    
Invasive Aspergillosis§6 mg/kg q12h for the first 24 hours4 mg/kg q12h200 mg q12h
    
Candidemia in nonneutropenic patients and other deep tissue Candida infections6 mg/kg q12h for the first 24 hours3–4 mg/kg q12h200 mg q12h
    
Esophageal Candidiasis##200 mg q12h
    
Scedosporiosis and Fusariosis6 mg/kg q12h for the first 24 hours4 mg/kg q12h200 mg q12h

Dosage Adjustment


If patient response is inadequate, the oral maintenance dose may be increased from 200 mg every 12 hours (similar to 3 mg/kg IV q12h) to 300 mg every 12 hours (similar to 4 mg/kg IV q12h). For adult patients weighing less than 40 kg, the oral maintenance dose may be increased from 100 mg every 12 hours to 150 mg every 12 hours. If patient is unable to tolerate 300 mg orally every 12 hours, reduce the oral maintenance dose by 50 mg steps to a minimum of 200 mg every 12 hours (or to 100 mg every 12 hours for adult patients weighing less than 40 kg).


If patient is unable to tolerate 4 mg/kg IV q12h, reduce the intravenous maintenance dose to 3 mg/kg q12h.


The maintenance dose of voriconazole should be increased when co-administered with phenytoin or efavirenz [see Drug Interactions (7)].


The maintenance dose of voriconazole should be reduced in patients with mild to moderate hepatic impairment, Child-Pugh Class A and B [see Dosage and Administration (2.7)]. There are no PK data to allow for dosage adjustment recommendations in patients with severe hepatic impairment (Child-Pugh Class C).


Duration of therapy should be based on the severity of the patient's underlying disease, recovery from immunosuppression, and clinical response.



Intravenous Administration



Reconstitution


The powder is reconstituted with 19 mL of Water For Injection to obtain an extractable volume of 20 mL of clear concentrate containing 10 mg/mL of voriconazole. It is recommended that a standard 20 mL (non-automated) syringe be used to ensure that the exact amount (19.0 mL) of Water for Injection is dispensed. Discard the vial if a vacuum does not pull the diluent into the vial. Shake the vial until all the powder is dissolved.



Dilution


Vfend must be infused over 1–2 hours, at a concentration of 5 mg/mL or less. Therefore, the required volume of the 10 mg/mL Vfend concentrate should be further diluted as follows (appropriate diluents listed below):


  1. Calculate the volume of 10 mg/mL Vfend concentrate required based on the patient's weight (see Table 2).

  2. In order to allow the required volume of Vfend concentrate to be added, withdraw and discard at least an equal volume of diluent from the infusion bag or bottle to be used. The volume of diluent remaining in the bag or bottle should be such that when the 10 mg/mL Vfend concentrate is added, the final concentration is not less than 0.5 mg/mL nor greater than 5 mg/mL.

  3. Using a suitable size syringe and aseptic technique, withdraw the required volume of Vfend concentrate from the appropriate number of vials and add to the infusion bag or bottle. Discard Partially Used Vials.

The final Vfend solution must be infused over 1–2 hours at a maximum rate of 3 mg/kg per hour.






































































Table 2: Required Volumes of 10 mg/mL Vfend Concentrate
Volume of Vfend Concentrate (10 mg/mL) required for:
Body Weight

(kg)
3 mg/kg dose

(number of vials)
4 mg/kg dose

(number of vials)
6 mg/kg dose

(number of vials)
309.0 mL (1)12 mL (1)18 mL (1)
3510.5 mL (1)14 mL (1)21 mL (2)
4012.0 mL (1)16 mL (1)24 mL (2)
4513.5 mL (1)18 mL (1)27 mL (2)
5015.0 mL (1)20 mL (1)30 mL (2)
5516.5 mL (1)22 mL (2)33 mL (2)
6018.0 mL (1)24 mL (2)36 mL (2)
6519.5 mL (1)26 mL (2)39 mL (2)
7021.0 mL (2)28 mL (2)42 mL (3)
7522.5 mL (2)30 mL (2)45 mL (3)
8024.0 mL (2)32 mL (2)48 mL (3)
8525.5 mL (2)34 mL (2)51 mL (3)
9027.0 mL (2)36 mL (2)54 mL (3)
9528.5 mL (2)38 mL (2)57 mL (3)
10030.0 mL (2)40 mL (2)60 mL (3)

Vfend I.V. for Injection is a single dose unpreserved sterile lyophile. Therefore, from a microbiological point of view, once reconstituted, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2° to 8°C (36° to 46°F). This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used.


The reconstituted solution can be diluted with:


9 mg/mL (0.9%) Sodium Chloride USP

Lactated Ringers USP

5% Dextrose and Lactated Ringers USP

5% Dextrose and 0.45% Sodium Chloride USP

5% Dextrose USP

5% Dextrose and 20 mEq Potassium Chloride USP

0.45% Sodium Chloride USP

5% Dextrose and 0.9% Sodium Chloride USP


The compatibility of Vfend I.V. with diluents other than those described above is unknown (see Incompatibilities below).


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.



Incompatibilities


Vfend I.V. must not be diluted with 4.2% Sodium Bicarbonate Infusion. The mildly alkaline nature of this diluent caused slight degradation of Vfend after 24 hours storage at room temperature. Although refrigerated storage is recommended following reconstitution, use of this diluent is not recommended as a precautionary measure. Compatibility with other concentrations is unknown.



Oral Suspension



Reconstitution


Tap the bottle to release the powder. Add 46 mL of water to the bottle. Shake the closed bottle vigorously for about 1 minute. Remove child-resistant cap and push bottle adaptor into the neck of the bottle. Replace the cap. Write the date of expiration of the reconstituted suspension on the bottle label (the shelf-life of the reconstituted suspension is 14 days at controlled room temperature 15–30°C [59–86°F]).



Instructions for use


Shake the closed bottle of reconstituted suspension for approximately 10 seconds before each use. The reconstituted oral suspension should only be administered using the oral dispenser supplied with each pack.



Incompatibilities


Vfend for Oral Suspension and the 40 mg/mL reconstituted oral suspension should not be mixed with any other medication or additional flavoring agent. It is not intended that the suspension be further diluted with water or other vehicles.



Use in Patients With Hepatic Impairment


In the clinical program, patients were included who had baseline liver function tests (ALT, AST) up to 5 times the upper limit of normal. No dose adjustment is necessary in patients with this degree of abnormal liver function, but continued monitoring of liver function tests for further elevations is recommended [see Warnings and Precautions (5.9)].


It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B) [see Clinical Pharmacology (12.3)].


Vfend has not been studied in patients with severe hepatic cirrhosis (Child-Pugh Class C) or in patients with chronic hepatitis B or chronic hepatitis C disease. Vfend has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and should only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with hepatic insufficiency must be carefully monitored for drug toxicity.



Use in Patients With Renal Impairment


The pharmacokinetics of orally administered Vfend are not significantly affected by renal impairment. Therefore, no adjustment is necessary for oral dosing in patients with mild to severe renal impairment [see Clinical Pharmacology (12.3 )].


In patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and, if increases occur, consideration should be given to changing to oral voriconazole therapy [see Warnings and Precautions (5.10)].


Voriconazole is hemodialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. A 4-hour hemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.



Dosage Forms and Strengths



Powder for Solution for Injection


Vfend I.V. for Injection is supplied in a single use vial as a sterile lyophilized powder equivalent to 200 mg Vfend and 3200 mg sulfobutyl ether beta-cyclodextrin sodium (SBECD).



Tablets


Vfend 50 mg tablets; white, film-coated, round, debossed with "Pfizer" on one side and "VOR50" on the reverse.


Vfend 200 mg tablets; white, film-coated, capsule shaped, debossed with "Pfizer" on one side and "VOR200" on the reverse.



Powder for Oral Suspension


Vfend for Oral Suspension is supplied in 100 mL high density polyethylene (HDPE) bottles. Each bottle contains 45 g of powder for oral suspension. Following reconstitution, the volume of the suspension is 75 mL, providing a usable volume of 70 mL (40 mg voriconazole/mL). A 5 mL oral dispenser and a press-in bottle adaptor are also provided.



Contraindications


  • Vfend is contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between Vfend (voriconazole) and other azole antifungal agents. Caution should be used when prescribing Vfend to patients with hypersensitivity to other azoles.

  • Coadministration of terfenadine, astemizole, cisapride, pimozide or quinidine with Vfend is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see Drug Interactions (7), and Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with sirolimus is contraindicated because Vfend significantly increases sirolimus concentrations [see Drug Interactions (7), and Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with rifampin, carbamazepine and long-acting barbiturates is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations significantly [see Drug Interactions (7), and Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with high-dose ritonavir (400 mg q12h) is contraindicated because ritonavir (400 mg q12h) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see Drug Interactions (7), and Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with rifabutin is contraindicated since Vfend significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations [see Drug Interactions (7), and Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because Vfend may increase the plasma concentration of ergot alkaloids, which may lead to ergotism [see Drug Interactions (7), Clinical Pharmacology (12.3)].

  • Coadministration of Vfend with St. John's Wort is contraindicated because this herbal supplement may decrease voriconazole plasma concentration [see Drug Interactions (7), and Clinical Pharmacology (12.3)].


Warnings and Precautions



Drug Interactions


See Table 7 for a listing of drugs that may significantly alter voriconazole concentrations. Also, see Table 8 for a listing of drugs that may interact with voriconazole resulting in altered pharmacokinetics or pharmacodynamics of the other drug [see Contraindications (4), and Drug Interactions (7)].



Hepatic Toxicity


In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with Vfend (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly hematological malignancy). Hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy [see Warnings and Precautions (5.9), and Adverse Reactions (6.3)].


Monitoring of hepatic function: Liver function tests should be evaluated at the start of and during the course of Vfend therapy. Patients who develop abnormal liver function tests during Vfend therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of Vfend must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to Vfend [see Warnings and Precautions (5.9), Dosage and Administration (2.4, 2.7), and Adverse Reactions (6.3)].



Visual Disturbances


The effect of Vfend on visual function is not known if treatment continues beyond 28 days. There have been post-marketing reports of prolonged visual adverse events, including optic neuritis and papilledema. If treatment continues beyond 28 days, visual function including visual acuity, visual field and color perception should be monitored [see Adverse Reactions (6.2)].



Pregnancy Category D


Voriconazole can cause fetal harm when administered to a pregnant woman.


In animals, voriconazole administration was associated with teratogenicity, embryotoxicity, increased gestational length, dystocia and embryomortality. Please refer to section 8.1 (Use in Pregnancy) for additional details.


If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to the fetus.



Galactose Intolerance


Vfend tablets contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.



Arrhythmias and QT Prolongation


Some azoles, including voriconazole, have been associated with prolongation of the QT interval on the electrocardiogram. During clinical development and post-marketing surveillance, there have been rare cases of arrhythmias, (including ventricular arrhythmias such as torsade de pointes), cardiac arrests and sudden deaths in patients taking voriconazole. These cases usually involved seriously ill patients with multiple confounding risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalemia and concomitant medications that may have been contributory.


Voriconazole should be administered with caution to patients with these potentially proarrhythmic conditions.


Rigorous attempts to correct potassium, magnesium and calcium should be made before starting voriconazole [see Clinical Pharmacology (12.3)].



Infusion Related Reactions


During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus and rash, have occurred uncommonly. Symptoms appeared immediately upon initiating the infusion. Consideration should be given to stopping the infusion should these reactions occur.



Laboratory Tests


Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of Vfend therapy.


Patient management should include laboratory evaluation of renal (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin).



Patients With Hepatic Impairment


It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B) receiving Vfend [see Clinical Pharmacology (12.3), and Dosage and Administration (2.7)].


Vfend has not been studied in patients with severe cirrhosis (Child-Pugh Class C). Vfend has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and should only be used in patients with severe hepatic insufficiency if the benefit outweighs the potential risk. Patients with hepatic insufficiency must be carefully monitored for drug toxicity.



Patients With Renal Impairment


In patients with moderate to severe renal dysfunction (creatinine clearance <50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and if increases occur, consideration should be given to changing to oral voriconazole therapy [see Clinical Pharmacology (12.3), and Dosage and Administration (2.8)].



Monitoring of Renal Function


Acute renal failure has been observed in patients undergoing treatment with Vfend. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function.


Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.



Monitoring of Pancreatic Function


Patients with risk factors for acute pancreatitis (e.g., recent chemotherapy, hematopoietic stem cell transplantation [HSCT]) should be monitored for the development of pancreatitis during Vfend treatment.



Dermatological Reactions


Serious exfoliative cutaneous reactions, such as Stevens-Johnson syndrome, have been reported during treatment with Vfend. If a patient develops an exfoliative cutaneous reaction, Vfend should be discontinued.


In addition Vfend has been associated with photosensitivity skin reaction. Patients should avoid intense or prolonged exposure to direct sunlight during Vfend treatment. In patients with photosensitivity skin reactions squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy. If a patient develops a skin lesion consistent with squamous cell carcinoma or melanoma, Vfend should be discontinued.



Skeletal Adverse Events


Fluorosis and periostitis have been reported during long-term voriconazole therapy. If a patient develops skeletal pain and radiologic findings compatible with fluorosis or periostitis, voriconazole should be discontinued [see Adverse Reactions (6.4)].



Adverse Reactions


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



Overview


The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%), hallucinations (2.4%). The treatment-related adverse events which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash, and visual disturbances [see Warning and Precautions (5.2, 5.3), and Adverse Reactions (6.2, 6.3)].



Clinical Trial Experience in Adults


The data described in Table 3 reflect exposure to voriconazole in 1655 patients in the therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and non-neutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11–90, including 51 patients aged 12–18 years), and was 78% White and 10% Black. Five hundred sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over six months. Table 3 includes all adverse events which were reported at an incidence of ≥2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined, or study 305, as well as events of concern which occurred at an incidence of <2%.


In study 307/602, 381 patients (196 on voriconazole, 185 on amphotericin B) were treated to compare voriconazole to amphotericin B followed by other licensed antifungal therapy in the primary treatment of patients with acute invasive aspergillosis. The rate of discontinuation from voriconazole study medication due to adverse events was 21.4% (42/196 patients). In study 608, 403 patients with candidemia were treated to compare voriconazole (272 patients) to the regimen of amphotericin B followed by fluconazole (131 patients). The rate of discontinuation from voriconazole study medication due to adverse events was 19.5% out of 272 patients. Study 305 evaluated the effects of oral voriconazole (200 patients) and oral fluconazole (191 patients) in the treatment of esophageal candidiasis. The rate of discontinuation from voriconazole study medication in Study 305 due to adverse events was 7% (14/200 patients). Laboratory test abnormalities for these studies are discussed under Clinical Laboratory Values below.















































































































































































































































































Table 3: Treatment Emergent Adverse Events Rate ≥ 2% on Voriconazole or Adverse Events of Concern in All Therapeutic Studies Population, Studies 307/602-608 Combined, or Study 305. Possibly Related to Therapy or Causality Unknown*
All Therapeutic StudiesStudies 307/602 and 608

(IV/ oral therapy)
Study 305

(oral therapy)
Voriconazole

N=1655
Voriconazole

N=468
Ampho B†

N=185
Ampho B→

Fluconazole

N=131
Voriconazole

N=200
Fluconazole

N=191
N (%)N (%)N (%)N (%)N (%)N (%)

*

Study 307/602: invasive aspergillosis; Study 608: candidemia; Study 305: esophageal candidiasis

†

Amphotericin B followed by other licensed antifungal therapy

‡

See Warnings and Precautions (5.3)

       
Special Senses‡
Abnormal vision310 (18.7)63 (13.5)1 (0.5)031 (15.5)8 (4.2)
Photophobia37 (2.2)8 (1.7)005 (2.5)2 (1.0)
Chromatopsia20 (1.2)2 (0.4)002 (1.0)0
       
Body as a Whole
Fever94 (5.7)8 (1.7)25 (13.5)5 (3.8)00
Chills61 (3.7)1 (0.2)36 (19.5)8 (6.1)1 (0.5)0
Headache49 (3.0)9 (1.9)8 (4.3)1 (0.8)01 (0.5)
       
Cardiovascular System
Tachycardia39 (2.4)6 (1.3)5 (2.7)000
       
Digestive System
Nausea89 (5.4)18 (3.8)29 (15.7)2 (1.5)2 (1.0)3 (1.6)
Vomiting72 (4.4)15 (3.2)18 (9.7)1 (0.8)2 (1.0)1 (0.5)
Liver function tests abnormal45 (2.7)15 (3.2)4 (2.2)1 (0.8)6 (3.0)2 (1.0)
Cholestatic jaundice17 (1.0)8 (1.7)01 (0.8)3 (1.5)0
       
Metabolic and Nutritional Systems
Alkaline phosphatase increased59 (3.6)19 (4.1)4 (2.2)3 (2.3)10 (5.0)3 (1.6)
Hepatic enzymes increased30 (1.8)11 (2.4)5 (2.7)1 (0.8)3 (1.5)0
SGOT increased31 (1.9)9 (1.9)01 (0.8)8 (4.0)2 (1.0)
SGPT increased29 (1.8)9 (1.9)1 (0.5)2 (1.5)6 (3.0)2 (1.0)
Hypokalemia26 (1.6)3 (0.6)36 (19.5)16 (12.2)00
Bilirubinemia15 (0.9)5 (1.1)3 (1.6)2 (1.5)1 (0.5)0
Creatinine increased4 (0.2)059 (31.9)10 (7.6)1 (0.5)0
       
Nervous System
Hallucinations39 (2.4)13 (2.8)1 (0.5)000
       
Skin and Appendages
Rash88 (5.3)20 (4.3)7 (3.8)1 (0.8)3 (1.5)1 (0.5)
       
Urogenital

Valcyte


Generic Name: valganciclovir (Oral route)

val-gan-SYE-kloe-vir

Oral route(Tablet;Powder for Solution)

The clinical toxicity of valganciclovir, which is metabolized to ganciclovir, includes granulocytopenia, anemia and thrombocytopenia. In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis .



Commonly used brand name(s)

In the U.S.


  • Valcyte

Available Dosage Forms:


  • Powder for Solution

  • Tablet

Therapeutic Class: Antiviral


Pharmacologic Class: Viral DNA Polymerase Inhibitor


Chemical Class: Guanosine Nucleoside Analog


Uses For Valcyte


Valganciclovir is used to treat symptoms of cytomegalovirus (CMV) retinitis, an infection in the eyes of people with acquired immunodeficiency syndrome (AIDS). Valganciclovir will not cure this eye infection, but it may help to keep the symptoms from becoming worse.


Valganciclovir is an antiviral. It is used to treat infections caused by viruses. This medicine is also used to prevent CMV disease in patients who have received an organ transplant (e.g., heart, kidney, or kidney-pancreas transplant).


This medicine may cause some serious side effects, including anemia and other blood problems. Before you begin treatment with valganciclovir, you and your doctor should talk about the benefit this medicine will do as well as the risks of using it.


This medicine is available only with your doctor's prescription.


Before Using Valcyte


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of valganciclovir for the prevention of CMV disease in kidney and heart transplant children. However, safety and efficacy of valganciclovir for the prevention of CMV disease have not been established in liver transplant children, and in kidney and heart transplant infants less than 4 months of age.


Geriatric


Although appropriate studies on the relationship of age to the effects of valganciclovir have not been performed in the geriatric population, no geriatric-specific problems have been documented to date. However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require caution and an adjustment in the dose for patients receiving valganciclovir.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Imipenem

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Didanosine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.


  • High Fat Food

Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Blood or bone marrow problems (e.g., anemia, bone marrow aplasia, leukopenia, neutropenia, pancytopenia, thrombocytopenia)—Use with caution. May make these conditions worse. or

  • Kidney disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

  • Kidney disease, severe (hemodialysis)—Should not be used in patients with this condition.

Proper Use of Valcyte


Take this medicine exactly as directed by your doctor. Do not change the dose or stop using this medicine without checking first with your doctor. When your supply of this medicine is running low, contact your doctor or pharmacist ahead of time. Do not allow yourself to run out of this medicine.


This medicine should come with a patient information insert. Read and follow these instructions carefully. Ask your doctor if you have any questions.


It is important that you take this medicine with food. This is to make sure the medicine is fully absorbed into the body and will work properly.


Swallow the tablet whole. Do not break, crush, or chew it.


Be careful not to handle crushed or broken tablets. If you have contact with broken or crushed tablets or mixed oral liquid, wash your skin with soap and clear water. If the medicine gets into your eyes, rinse them with clear water.


If you are using the oral liquid, use the oral dispenser that comes with the package to measure each dose accurately. The average household teaspoon may not hold the right amount of liquid.


If you are taking ganciclovir (Cytovene®) capsules before switching to valganciclovir (Valcyte®) tablets, the dose of your medicine may change. Although these medicines both treat the same problem, they are absorbed differently by your body. Make sure you understand the new directions for Valcyte® so you do not take too many tablets.


To get the best results, valganciclovir must be given for the full time of treatment. Also, this medicine works best when there is a constant amount in the blood. To help keep the amount constant, valganciclovir must be taken on a regular schedule.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage forms (solution and tablets):
    • For treatment of CMV infection in the eyes:
      • Adults—At first, 900 milligrams (mg) (two 450 mg tablets) two times a day for 21 days. Then, your doctor may adjust your dose to 900 mg once a day.

      • Children—Use and dose must be determined by your doctor.


    • For prevention of CMV disease in transplant patients:
      • Adults who have received heart or kidney-pancreas transplant—900 milligrams (mg) (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days after transplantation.

      • Adults who have received kidney transplant—900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 200 days after transplantation.

      • Teenagers and children 4 months to 16 years of age who have received heart or kidney transplant—Dose given once a day starting within 10 days of transplantation until 100 days after transplantation is based on body size and creatinine clearance which must be determined by your doctor. However, the dose is usually not more than 900 mg once a day.

      • Infants younger than 4 months old—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Store the mixed oral liquid in the refrigerator. Do not freeze. Throw away any unused medicine after 49 days through community take-back programs when available.


Precautions While Using Valcyte


It is very important that your doctor check the progress of you or your child at regular visits to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.


Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. You should not become pregnant while you are taking this medicine and for at least 1 month after stopping it. Also, men should use a condom during treatment with this medicine and for at least 90 days after treatment has been completed. If you think you have become pregnant while using the medicine, tell your doctor right away.


If you plan to have children, talk with your doctor before using this medicine. Some men and women using this medicine have become infertile (unable to have children).


Valganciclovir can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:


  • If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

  • Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in the urine or stools; or pinpoint red spots on your skin.

  • Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

  • Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

  • Avoid contact sports or other situations where bruising or injury could occur.

This medicine may cause kidney failure, especially in elderly patients with kidney problems. Check with your doctor right away if you have the following symptoms: agitation, coma, confusion, decreased urine output, depression, dizziness, headache, hostility, irritability, lethargy, muscle twitching, nausea, rapid weight gain, seizures, stupor, or swelling of the face, ankles, or hands.


This medicine may cause confusion, seizures, dizziness, drowsiness, or trouble in controlling movements. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Valcyte Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Black, tarry stools

  • blood in the urine or stools

  • blurred vision

  • chills

  • cough

  • dizziness

  • fever

  • headache

  • hoarseness

  • lower back or side pain

  • nervousness

  • painful or difficult urination

  • pale skin

  • pinpoint red spots on the skin

  • pounding in the ears

  • seeing flashes or sparks of light

  • seeing floating spots before the eyes

  • shakiness in the legs, arms, hands, or feet

  • shortness of breath

  • slow or fast heartbeat

  • sore throat

  • trembling or shaking of the hands or feet

  • troubled breathing

  • troubled breathing with exertion

  • ulcers, sores, or white spots in the mouth

  • unusual bleeding or bruising

  • unusual tiredness or weakness

  • veil or curtain appearing across part of vision

Less common
  • Changes in facial skin color

  • confusion

  • false beliefs

  • fast or irregular breathing

  • feeling, hearing, or seeing things that are not there

  • hives, itching, and skin rash

  • large, hive-like swellings on the eyelids, face, lips, mouth, or tongue

  • puffiness or swelling of the eyelids or around the eyes

  • runny or stuffy nose

  • seizures

  • tightness in the chest or wheezing

  • trouble thinking

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Abdominal or stomach pain

  • diarrhea

  • headache

  • nausea and vomiting

  • numbness, tingling, pain, or weakness of the hands or feet

  • sleeplessness

  • tingling, burning, or prickly sensations

  • trouble with sleeping

  • unsteadiness or awkwardness

Less common
  • Agitation

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Valcyte side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Valcyte resources


  • Valcyte Side Effects (in more detail)
  • Valcyte Use in Pregnancy & Breastfeeding
  • Drug Images
  • Valcyte Drug Interactions
  • Valcyte Support Group
  • 0 Reviews for Valcyte - Add your own review/rating


  • Valcyte Prescribing Information (FDA)

  • Valcyte MedFacts Consumer Leaflet (Wolters Kluwer)

  • Valcyte Concise Consumer Information (Cerner Multum)

  • Valcyte Monograph (AHFS DI)

  • Valganciclovir Professional Patient Advice (Wolters Kluwer)



Compare Valcyte with other medications


  • CMV Retinitis
  • Cytomegalovirus Infection